ð€ïŒããã©ã»ãå¯Ÿç §è©Šéšã®è¢«éšè çã«å¯Ÿããå«ççé æ ®ã«ã€ããŠã
æ°åã³ãããŠã€ã«ã¹(SARS-CoV-2)ã¯ã¯ãã³ã®è©äŸ¡ã«é¢ããèãæ¹(è£éº 2) ãã©ã»ã察ç
§è©Šéšã®è¢«éšè
çã«å¯Ÿããå«ççé
æ
®ã«ã€ããŠ
什å3幎6æ11æ¥ ç¬ç«è¡æ¿æ³äººå»è¬åå»çæ©åšç·åæ©æ§ ã¯ã¯ãã³ç審æ»éš
1. ã¯ããã«
2020 幎 12 æ 2 æ¥ã«è±åœã«ãããŠåã㊠SARS-CoV-2 ã¯ã¯ãã³ãäžæçèªå¯ãããŠä»¥æ¥ã
äžçååœåã³å°åã§ã¯è€æ°ã®ã¯ã¯ãã³ãç·æ¥äœ¿çšèš±å¯åã¯æ¿èªãããŠãããã¯ã¯ãã³æ¥çš® ã¯æ¥éã«é²ãã§ãããæãåœã«ãããŠã什å 3 幎 2 æ 14 æ¥ã«æåã® SARS-CoV-2 ã¯ã¯ãã³ ãæ¿èªãããŠä»¥éãåœå
ã§ã®æ¥çš®äººå£ãæ¡ããããã®æ§ã
ãªåªåããªãããŠããã
ãã®ã¯ã¯ãã³ã®éçºã«éããŠãèšåºè©Šéšã«ãããæå¹æ§åã³å®å
šæ§ã®è©äŸ¡ã¯äžå¯æ¬ ã§ã ãããã®äžã§ããã©ã»ã察ç
§èšåºè©Šéšã¯ããã©ã»ã矀ãèšå®ãç²æ€ååã³ã©ã³ãã åãå°å
¥ ããããšã§è¢«éšè¬ã®è¬çäœçšä»¥å€ã®ãã¹ãŠã®æœåšçãªåœ±é¿ãã³ã³ãããŒã«ããããšãå¯èœ ã§ãã 1)ãããä¿¡é Œæ§ã®é«ããšããã³ã¹æ§ç¯ã«ãããŠæ¥µããŠæçšãªæ段ã§ããã
äžæ¹ã§ããã©ã»ãã®äœ¿çšã«ã¯ãå«ççãªé
æ
®ãæ±ãããããäŸãã°ããã«ã·ã³ã宣èšã§ã¯ã ãã©ã»ãã®èšåºè©Šéšã§ã®äœ¿çšã«ã€ããŠãæåãšèšŒæãããæ²»çãåããªãã£ãçµæãšããŠã é節åã¯å埩äžèœãªæ害ã®ä»å çãªã¹ã¯ã被ãããšããªããšäºæ³ãããå Žåã«éããã 2) ãšãããŠãããæãåœã§ã¯ SARS-CoV-2 ã¯ã¯ãã³ã®å
¬çæ¥çš®ããã°ã©ã (以äžãå
¬çæ¥çš®ã ãã°ã©ã ããšããã)ãéå§ãããŠãããä»åŸãã¯ã¯ãã³ãåœæ°ã«æ®åããŠããããšãèæ
® ãããšãããããå®æœãããèšåºè©Šéšã«ãããŠãã©ã»ã矀ãèšå®ããå Žåã®ã¿ãªãããã㧠ã«å®æœãããŠããèšåºè©Šéšã«ãããŠãã©ã»ããæ¥çš®ããã被éšè
çã«å¯ŸããŠããäœããã® æåã®å»çãåŸãããããå«ççãªé
æ
®ãå¿
èŠã§ããã
ããã§æ¬ææžã§ã¯ãæãåœã§ãã§ã«å®æœãããŠãããåã¯ä»åŸå®æœããã SARS-CoV-2 㯠ã¯ãã³éçºã«ä¿ãèšåºè©Šéšã«ãããŠããã©ã»ã矀ãèšå®ããéçã®å«ççé
æ
®ã«ã€ããŠäŸ 瀺ããããšãšããã以äžã«ç€ºãæ¹æ³ä»¥å€ã«ããäŸãã°è¢«éšè¬ã®æå¹æ§ã瀺ãããå Žåã¯ç²æ€ åã¯ãã¹ãªãŒããŒãã¶ã€ã³ã«å€æŽããçãå«ççé
æ
®ãè¡ãæ¹æ³ã¯èãåŸããä»®ã«ä»¥äžã«ç€º ãæ¹æ³ä»¥å€ã®æ¹æ³ã§ããã©ã»ããæ¥çš®ããã被éšè
çã«å¯ŸããŠå«ççé
æ
®ãè¡ãããšãäŒ å³ããŠããå Žåã¯ãå¿
èŠã«å¿ããŠç¬ç«è¡æ¿æ³äººå»è¬åå»çæ©åšç·åæ©æ§ã«çžè«ãæèŠãæ± ããããšãã§ããã
ãªããæ¬ææžã®å
容ããæ°åã³ãããŠã€ã«ã¹(SARS-CoV-2)ã¯ã¯ãã³ã®è©äŸ¡ã«é¢ããè ãæ¹ã(什å 2 幎 9 æ 2 æ¥å»è¬åå»çæ©åšç·åæ©æ§ã¯ã¯ãã³ç審æ»éš)ãšéè€ããå Žåã¯ã æ¬ææžãåªå
ããã
ãŸããæ¬ææžã«ç€ºãèãæ¹ã¯ 2021 幎 5 ææç¹ã§ã®æãåœã§ã®ç€ŸäŒçãªç¶æ³ãèžãŸããŠæ€ 1
èšãå°é家ãšã®æèŠäº€æãçµãŠäœæãããã®ã§ãããä»åŸã®æãåœã«ããã COVID-19 ã® æµè¡ç¶æ³ãSARS-CoV-2 ã¯ã¯ãã³éçºç¶æ³åã³å
¬çæ¥çš®ããã°ã©ã ã®é²æç¶æ³çã«ãã£ãŠå€ ããåŸããã®ã§ããããšã«çæããããã
2. ãã§ã«å®æœããŠããèšåºè©Šéšã§ã®å¯Ÿå¿ã«ã€ããŠ
2.1. å«ççé
æ
®ãšããŠèæ
®ãã¹ãäºé
ãšæ²»éšèšç»çã®å€æŽ
SARS-CoV-2 ã¯ã¯ãã³ã«é¢ããèšåºè©Šéšã®è¢«éšè
ã«å¯Ÿããå«ççé
æ
®ãšããŠã¯ãæ¥çš®ãã ãæ²»éšè¬(被éšè¬åã³ãã©ã»ã)ã«ãã COVID-19 ã®äºé²ãæåŸ
ã§ããªãè
ã«å¯ŸããŠã COVID-19 ã®äºé²ãå¯èœãªæ段ãããããšãæ
å ±æäŸããããšã被éšè
ãèªãã®çœ®ãããç¶ æ³ãç解ããããã®å©èšãè¡ãããšãCOVID-19 ã®äºé²ã®ããã®æ段ãæäŸããããšçãè ããããã
ãã®ãããªæ
å ±æäŸãå©èšã被éšè
ã«å¯ŸããŠè¡ãéã«ã¯ãå被éšè
ãã©ã®æ¥çš®çŸ€ã«å±ã ãŠããã®ããæ¬äººã«äŒéããå¿
èŠãçãããäŒéã«ã€ããŠã¯ãæ¥çš®çŸ€æ¯ã«å²ãåœãŠããã被 éšè
ã«äžæã«äŒéããããšãã被éšè
ããç³ãåºããã床ã«åå¥ã«äŒéããããšãæ³å®ã ããã
ãã®éãåœè©²è©Šéšãç²æ€åããããã®ã§ãã£ãå Žåãç²æ€ç¶æ
ã解é€ããªããã°ãªããªã å ŽåãçãåŸããæ²»éšäŸé Œè
ãå«ççé
æ
®ã®ããã«èšåºè©Šéšã®ç²æ€è§£é€ã決ããå Žåãæ²»éš äŸé Œè
ã¯ãåœåèšç»ããæ²»éšå®æœèšç»æžã«ããã解æèšç»ãæ€äœæ¡ååã³å®å
šæ§æ
å ±åéã® èšç»ã䞊ã³ã«æãåœã§ã®å
¬çæ¥çš®ããã°ã©ã ã®é²æãèžãŸããã©ã®ææãŸã§ç²æ€ãç¶æãã ããšãèšåºè©Šéšã®ç§åŠçãªäŸ¡å€ãä¿ã¡ãå«ççãªé
æ
®ãšãã©ã³ã¹ãåãããšãã§ãããæ€ èšããç²æ€è§£é€ãå¿
èŠãªææãæ€èšããå¿
èŠãããã
ãŸããæ²»éšå®æœèšç»æžãåæ説æææžçã«ã被éšè
ãå±ããŠããæ¥çš®çŸ€ãæ¬äººã«é瀺ãã æé ã被éšè
èªèº«ãå±ããŠããæ¥çš®çŸ€ãç¥ãããã®æé ãå«ãŸããŠããªãå Žåã¯ããããæ æžã®å€æŽãè¡ããšãšãã«ã被éšè
ã«å¯ŸããŠãæ¬äººãå±ããŠããæ¥çš®çŸ€ãç¥ãããã®æé ãæ
å ±æäŸããå¿
èŠãããããŸããCOVID-19 ã®äºé²ã®ããã®æ段ã®æäŸãšããŠã2.3.1.åã³ 2.4.1. ã®åé
ã«åºã¥ããã©ã»ã矀çã®è¢«éšè
ã«è¢«éšè¬ãæ¥çš®ããéã«ã¯ããã®ç¹ã䜵ããŠèšç»ã å€æŽãã¹ãã§ããã
2.2. å
·äœçãªç²æ€è§£é€ã®ææã«ã€ããŠ
å
¬çæ¥çš®ããã°ã©ã ã¯ãCOVID-19 ã®éçåãªã¹ã¯ã®é«ãè
(以äžããã€ãªã¹ã¯è
ããšã
ãã)ããé 次è¡ãããèšç»ãšãããŠããã»ããè·åæ¥çš®çã®å€æ§ãªæ¥çš®ä¿é²çãæ€èšãã ãŠããããã®ããã被éšè¬åã³ãã©ã»ãæ¥çš®åŸã®å®å
šæ§æ
å ±çãå¯èœãªéãåéãã芳ç¹ã ããç²æ€è§£é€ã®ææã¯ãå
¬çæ¥çš®ããã°ã©ã ã®é²æã«åãããå»çåŸäºè
ãé«éœ¢è
åã³åºç€ çŸæ£ãæã€è
çãCOVID-19 ã®æ¥çš®ã®åªå
é äœã®é«ãè
ããé 次ç²æ€è§£é€ããããšãæåŸ
ã ãããäžæ¹ã§ãå
¬çæ¥çš®ããã°ã©ã ã®é²æç¶æ³åã¯è©Šéšã®ã³ããŒãã®èšå®ã«ãã£ãŠã¯ãäžæ ã«ç²æ€è§£é€ããå¿
èŠãããå Žåããåå¥ã®è¢«éšè
æ¯ã®ç²æ€è§£é€ãåççãªå Žåãèããã
2
ããããåå¥ã®èšåºè©Šéšã«å¿ããŠæè»ã«ç²æ€è§£é€ææã察象ãæ€èšãã¹ãã§ããã
2.3. ãã©ã»ã矀ã«å²ãåœãŠããã被éšè
ãžã®é
æ
®ã«ã€ã㊠2.3.1. 被éšè
ã«å¯Ÿããæ
å ±æäŸåã³å¿
èŠãªæªçœ®ã«ã€ããŠ
æ²»éšäŸé Œè
ã COVID-19 ã®äºé²ã®ããã®æ段ãæäŸããæ¹æ³ãæ€èšããéã被éšè¬ãã ã§ã«åœå
å€ã§æ¿èªåã¯ç·æ¥äœ¿çšèš±å¯çãããŠããã®ã§ããã°ãæ²»éšäŸé Œè
ã¯ããã©ã»ã矀㮠被éšè
ã«å¯Ÿã被éšè¬ã®æ¥çš®æ©äŒãæäŸããããšãæãŸããã被éšè¬ã®æäŸãå°é£ãªå Žåã« ã¯ãå
¬çæ¥çš®ããã°ã©ã ãžã®åå ãæ€èšããããå©èšããããšããCOVID-19 ã®äºé²ã®ãã ã®æ段ãæäŸããæ¹æ³ã®äžã€ãšããŠèããããã
COVID-19 ã®äºé²ã®ããã®æ段ãæäŸããæ¹æ³ãšããŠè¢«éšè¬ã®æ¥çš®ãè¡ãå Žåã¯ãæ²»éšè²¬ ä»»å»åž«ãæ²»éšåæ
å»åž«ãæ²»éšååè
ãã®ä»æ²»éšã®éå¶ã«é¢ããè
(以äžãæ²»éšè²¬ä»»å»åž«çã ãšããã)ã¯è¢«éšè
ã«å¯ŸããŠã被éšè¬ã«é¢ããææ°ã®æ
å ±(æå¹æ§ãå®å
šæ§åã³æãåœã§ã® éçºç¶æ³ãè«žå€åœã«ããã䜿çšç¶æ³ç)ãåããããã説æããå¿
èŠãããããŸããæ²»éšäŸ é Œè
ã¯ã被éšè
ãžã®èª¬æã«è³ããæ
å ±ããæ²»éšè²¬ä»»å»åž«çã«æäŸããå¿
èŠãããã
ãªããæ²»éšäŸé Œè
ã¯ã被éšè¬ãè¿œå çã«æ¥çš®ãã被éšè
ãå
¬çæ¥çš®ããã°ã©ã ã«åå ã㪠ãã£ãéã«äžå©çã被ããªããããªæªçœ®ãè¬ããå¿
èŠããããäŸãã°ãçŸåšåœéçãªæ€èšã ãªãããŠããå
¬çãªäºé²æ¥çš®èšŒæãæãåœã«å°å
¥ãããæã«åããŠèŠå¶åœå±ãšçžè«ããã ãšããæ¥çš®ãã被éšè¬åã³æ¥çš®æ¥çãèšèŒãããææžãçºè¡ãããããæ²»éšè²¬ä»»å»åž«çã«äŸ é Œããçã®å¯Ÿå¿ã¯ãæªçœ®ã®äžäŸãšããŠèããããã
2.3.2. å«ççé
æ
®ãšããŠè¢«éšè¬ãè¿œå çã«æ¥çš®ããè
ããã®æ
å ±åéã«ã€ã㊠2.3.1.ã®èšèŒã«åºã¥ããå«ççé
æ
®ãšããŠè¢«éšè¬ãè¿œå çã«æ¥çš®ããå Žåãæ²»éšäŸé Œè
ã¯ã æ²»éšè²¬ä»»å»åž«çã«å¯ŸããŠã被éšè
ããã®è¢«éšè¬ã®å®å
šæ§ã«ä¿ãçžè«ãããã°å¯Ÿå¿ãããšãš ãã«ãå®å
šæ§æ
å ±ãåéããçã被éšè
ã®å®å
šæ§ãé©åã«ç®¡çããäœå¶ãæŽããããäŸé Œã
ãã
ãŸããæ²»éšäŸé Œè
ã¯ãäºå®ãããçšæ³ã»çšéã§è¢«éšè¬ãæ¥çš®ããåŸã7 æ¥éã«èªãããã
ç¹å®ã®å±æåå¿(è
«è¹ãçºèµ€ã硬çµãçŒçç)åã³ç¹å®ã®å
šèº«åå¿(çºç±ãé çãåŠæ æã çèçç)ã被éšè¬æ¥çš®ããæŠã 28 æ¥éã«èªããããæ害äºè±¡åã³ãã®ä»ã®æ害äºè±¡ãå éããããšãæãŸããããã ããåœè©²è¢«éšè¬ããã§ã«åœå
å€ã§æ¿èªåã¯ç·æ¥äœ¿çšèš±å¯çãã ãŠããå Žåã¯ãæ²»éšã«ãããéåžžã®å®å
šæ§ç£èŠæŽ»åã«åºã¥ããŠæ害äºè±¡çã®å®å
šæ§æ
å ±å éãè¡ãããšã§ããããªãããããã®è¢«éšè¬ãè¿œå çã«æ¥çš®ãã被éšè
ã®å
ç«åæ§ã«ã€ã㊠ã¯ãæ¹ããŠæ
å ±ãåéããå¿
èŠã¯ãªãã
2.4. 被éšè¬çŸ€ã«å²ãåœãŠããã被éšè
ãžã®é
æ
®ã«ã€ã㊠2.4.1. 被éšè
ã«å¯Ÿããæ
å ±æäŸåã³å¿
èŠãªæªçœ®ã«ã€ããŠ
被éšè¬ããã§ã«åœå
å€ã§æ¿èªåã¯ç·æ¥äœ¿çšèš±å¯çãããŠããå Žåãæ¿èªåã¯ç·æ¥äœ¿çšèš±
3
å¯çãããçšæ³ã»çšéã§è¢«éšè¬ã®æ¥çš®ãåãã被éšè
ã¯ãå
¬çæ¥çš®ããã°ã©ã ã«åå ããå¿
èŠã¯ãªãå¯èœæ§ãé«ãã
äžæ¹ã§ã被éšè¬çŸ€ã«å²ãåœãŠããã被éšè
ã®ãã¡ãæ¿èªåã¯ç·æ¥äœ¿çšèš±å¯çãèŠèŸŒãŸãã çšæ³ã»çšéã§ã¯ãªãæ¥çš®çŸ€ã«å²ãåœãŠãããŠããè
ã¯ããã©ã»ã矀ãšåæ§ã«ãå
¬çæ¥çš®ãã ã°ã©ã ãžã®åå åã¯è¢«éšè¬ã®æ¥çš®ãå¿
èŠãšèããããããŸãããããªãçšæ³ã»çšéã«ãã㊠ãã被éšè¬ã®æå¹æ§ãäžååãåã¯ç¢ºèªã§ããªãå¯èœæ§ããããšå€æããå Žåã¯ã被éšè¬ã® æ¥çš®ãåãã被éšè
å
šäœã«å¯ŸããŠãå
¬çæ¥çš®ããã°ã©ã ãžã®éãããªåå ãåŒã³æããå¿
èŠãããã
åŸè
ã®è¢«éšè
ã«å¯Ÿããå«ççãªé
æ
®ã«ã€ããŠã¯ãåºæ¬çã«ãã©ã»ã矀ã®è¢«éšè
ãšåæ§ã§ ããã2.3.é
ã®åèšèŒãåèã«å¯Ÿå¿ããå¿
èŠãããããã®éãæ¢æ¥çš®ã®è¢«éšè¬ã®åœ±é¿ã«ã€ã ãŠãèæ
®ããäžã§è¢«éšè
ãžã®æ
å ±æäŸã被éšè¬ã®æ¥çš®çãè¡ãå¿
èŠãããã
2.4.2. 被éšè¬çŸ€ã«å²ãåœãŠããã被éšè
ããã®æ
å ±åéã«ã€ã㊠被éšè¬çŸ€ã«å²ãåœãŠããã被éšè
(2.3.1.åã³ 2.4.1.ã®èšèŒã«åºã¥ãå«ççé
æ
®ã«ãã£ãŠè¢«
éšè¬ã®æ¥çš®æ©äŒãæäŸãããè
ãé€ã)ã«ã€ããŠã¯ãæ¥çš®ãããçšæ³ã»çšéã§æå¹æ§ãäžå ååã¯ç¢ºèªã§ããªããšå€æãããå Žåãé€ããå¯èœãªéãåœåã®æ²»éšå®æœèšç»æžã«åºã¥ãã å®å
šæ§æ
å ±åéãæ€äœæ¡ååã³è§£æèšç»ãç¶ç¶ããããšãæãŸããããã®ãããæ²»éšäŸé Œè
ã¯ãæ²»éšè²¬ä»»å»åž«çã 2.1.ã«åºã¥ããŠæ²»éšå®æœèšç»ã®å€æŽã«é¢ããæ
å ±æäŸãè¡ãéã«ãèš åºè©Šéšãžã®åå ãç¶ç¶ããããšäžŠã³ã«èšåºè©Šéšã«ãããå®å
šæ§æ
å ±åéåã³æ€äœæ¡åã®æ 矩ã«ã€ããŠã®èª¬æã䜵ããŠè¡ãããããæ²»éšè²¬ä»»å»åž«çãæ¯æŽããããšãæãŸããã
3. ä»åŸå®æœãããèšåºè©Šéšã§ãã©ã»ãã䜿çšããå Žåã®å¯Ÿå¿ã«ã€ããŠ
ä»åŸå®æœããã SARS-CoV-2 ã¯ã¯ãã³ã®èšåºè©Šéšã«ãããŠããç¶æ³ã«ãã£ãŠã¯è¢«éšè
ã« ãã©ã»ããæ¥çš®ããããšãå«ççã«èš±å®¹ãããã±ãŒã¹ã¯æ³å®ããããäŸãã°ããã©ã»ã察ç
§ è©Šéšã§ãªããã°è§£æ±ºã§ããªãèšåºäžã®åé¡ããããšããSARS-CoV-2 ã¯ã¯ãã³æ¥çš®ãé
ã㊠ãä¿å¥è¡çäžã®åé¡ããªããšãçãæ³å®ããã 3)ãå
·äœçã«ã¯ãå
¬çæ¥çš®ããã°ã©ã ãéå§ ãããŠããªãéå£ã察象ãšããèšåºè©Šéšãè¡ãå ŽåãçŸæç¹ã§ SARS-CoV-2 ã¯ã¯ãã³ã®æ å¹æ§åã³å®å
šæ§ã確ç«ããŠããªãéå£ã察象ãšããèšåºè©Šéšãè¡ãå Žååã¯è¿œå å
ç«ãç®
çã« SARS-CoV-2 ã¯ã¯ãã³ã®æ¢æ¥çš®è
çã察象ãšããèšåºè©Šéšãè¡ãå Žåçãèããããã ãããã®å Žåã¯ã2.ã§èšèŒããå
容ãèžãŸãã被éšè
ã«å¯Ÿããå«ççé
æ
®ã«ã€ããŠããã ãããæ²»éšå®æœèšç»æžã«å®ããåæ説æææžçã«ãé©åã«åæ ãããŠããå¿
èŠãããã
4
4.è¬èŸ æ¬ææžã¯ã以äžã®å°é家ããã®æèŠã®èŽåãçµãŠäœæããããã®ã§ãããããã«åã埡瀌
ç³ãäžããã
å°Ÿå
äžä¿¡ å€§åº å¹žæ²»
å²¡ç° è³¢åž
å²¡éš ä¿¡åœŠ
æ¿±ç° ç¯€é
æ éŠåœŠ
(æ¬ç§°ç¥)
å·åŽå»ççŠç¥å€§åŠ å»ççŠç¥åŠéšåã©ãå»ççŠç¥åŠç§ ç¹ä»»ææ åœç«å€§åŠæ³äººæ±äº¬å€§åŠå€§åŠé¢ æ
å ±åŠç°/å»åŠç³»ç 究ç§çç©çµ±èšåŠåé(å
Œ)åææ çŠå²¡çè·å€§åŠ åºç€ã»åºç€çè·éšé åºç€ã»å°éåºç€åé ææ å·åŽåžå¥åº·å®å
šç 究æ æé·
æ±äº¬å»ç§å€§åŠç
é¢ æž¡èªè
å»çã»ã³ã¿ãŒ ç¹ä»»ææ åœç«å€§åŠæ³äººçŸ€éŠ¬å€§åŠå€§åŠé¢ ä¿å¥åŠç ç©¶ç§ ææ
1)ãèšåºè©Šéšã«ããã察ç
§çŸ€ã®éžæãšããã«é¢é£ããè«žåé¡ãã«ã€ããŠ(å¹³æ 13 幎 2 æ 27 æ¥ä»ãå»è¬å¯©çºç¬¬ 136 å·å¯©æ»ç®¡ç課é·éç¥)
2)ãã«ã·ã³ãå®£èš äººéã察象ãšããå»åŠç 究ã®å«ççåå(1964 幎 6 ææ¡æã2013 幎 10 ææ¹å®)
3)Emergency Use Designation of COVID-19 candidate vaccines: Ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding, WHO, December 2020
ãã®èšäºãæ°ã«å ¥ã£ãããµããŒããããŠã¿ãŸãããïŒ